Síndrome de Fahr por hipoparatiroidismo secundario / Fahr syndrome due to secondary hypoparatiroidism

Objetivo: Describir la obtención del diagnóstico etiológico del síndrome de Fahr en una paciente sin antecedentes familiares de calcificaciones cerebrales.Caso clínico: Se presenta una paciente que ingresó con trastornos psiquiátricos,convulsiones y movimientos involuntarios. Se le realizó una tomografía computarizada de cráneo donde fue evidente gruesas y simétricas calcificaciones en ganglios basales,cerebelo y en sustancia blanca. Se diagnosticó un síndrome de Fahr por hipoparatiroidismo secundario debido a las lesiones observadas, los resultados de las pruebas hormonales y losantecedentes de tiroidectomía de varios años atrás. Fue tratada con gluconato de calcio y fenitoína. Falleció posteriormente por shock cardiogénico.Conclusión: El análisis de las características clínicas, los hallazgos de neuroimagen, las pruebas de laboratorio, los resultados anatomopatológicos y antecedentes quirúrgicos, permitieron el diagnóstico etiológico del síndrome de Fahr en esta paciente(AU)

Objective: To describe the etiological diagnosis process of Fahr syndrome in a patient with no family history of brain calcifications.Clinical case report: We report a female patient who was admitted because of psychiatric disorders, seizures and involuntary movements. A computed tomography scan of the skull was performed, which showed thick and symmetrical calcifications in the basal ganglia, cerebellum, and white matter. Fahr syndrome was diagnosed from secondary hypoparathyroidism because of the injuries observed, the results of hormonal tests, and a history of thyroidectomy from several years. She was treated with calcium gluconate andphenytoin, and subsequently died of cardiogenic shock.Conclusions: The analysis of the clinical characteristics, the neuroimaging findings, the laboratory tests, the pathological results and the surgical history, allowed the etiologicaldiagnosis of Fahr syndrome in this patient(AU)

Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage. / Efecto del inhibidor de amida hidrolasa de ácidos grasos en el daño neuronal dopaminérgico inducido por MPTP.

INTRODUCTION: Parkinson's disease (PD) is a neurodegenerative disorder characterised by balance problems, muscle rigidity, and slow movement due to low dopamine levels and loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The endocannabinoid system is known to modulate the nigrostriatal pathway through endogenous ligands such as anandamide (AEA), which is hydrolysed by fatty acid amide hydrolase (FAAH). The purpose of this study was to increase AEA levels using FAAH inhibitor URB597 to evaluate the modulatory effect of AEA on dopaminergic neuronal death induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). METHODS: Our study included 4 experimental groups (n = 6 mice per group): a control group receiving no treatment, a group receiving URB597 (0.2mg/kg) every 3 days for 30 days, a group treated with MPTP (30mg/kg) for 5 days, and a group receiving URB597 and subsequently MPTP injections. Three days after the last dose, we conducted a series of behavioural tests (beam test, pole test, and stride length test) to compare motor coordination between groups. We subsequently analysed immunoreactivity of dopaminergic cells and microglia in the SNpc and striatum. RESULTS: Mice treated with URB597 plus MPTP were found to perform better on behavioural tests than mice receiving MPTP only. According to the immunohistochemistry study, mice receiving MPTP showed fewer dopaminergic cells and fibres in the SNpc and striatum. Animals treated with URB597 plus MPTP displayed increased tyrosine hydroxylase immunoreactivity compared to those treated with MPTP only. Regarding microglial immunoreactivity, the group receiving MPTP showed higher Iba1 immunoreactivity in the striatum and SNpc than did the group treated with URB597 plus MPTP. CONCLUSION: Our results show that URB597 exerts a protective effect since it inhibits dopaminergic neuronal death, decreases microglial immunoreactivity, and improves MPTP-induced motor alterations.

Efeitos dos anabolizantes sobre a densidade de neurônios dos núcleos da base / Effects of anabolic agents on the neuron density of the basal nuclei / Efectos de los anabolizantes en la densidad de las neuronas de los núcleos basales

RESUMO Objetivos: Pouco se sabe sobre a atuação dos esteroides androgênicos anabolizantes (EAA) no cérebro humano e, por isso, resolvemos estudar a perda neuronal causada pelo uso e abuso de EAA em camundongos. Métodos: Utilizamos 60 camundongos da linhagem Swiss, sendo 30 machos e 30 fêmeas, divididos em três grupos: 20 animais foram tratados com Deposteron® (cipionato de testosterona); outros 20 animais foram tratados com Winstrol Depot® (stanozolol); os últimos 20 animais foram tratados com solução salina. Todos foram submetidos à natação por 15 minutos. Finalizado o tratamento, os animais foram sacrificados pelo método de inalação de Halotano. Os encéfalos foram retirados e armazenados em solução de formaldeído a 4% por 24 horas. De cada encéfalo foram retiradas amostras homotípicas da região média do cérebro em cortes frontais para que pudéssemos avaliar as áreas estabelecidas para este estudo. Resultados: As análises da estimativa dos perfis celulares mostraram que houve uma diminuição do número de perfis no núcleo pálido dos animais machos tratados com Winstrol Depot®. Conclusão: Esses resultados nos permitem inferir que o uso inadequado e sem orientação médica de EAA pode levar a degenerações celulares.

ABSTRACT Objectives: Little is known about the action of anabolic-androgenic steroids (AAS) on the human brain and, therefore, we decided to study the neuronal loss caused by use and abuse of AAS in mice. Methods: We used 60 Swiss mice, 30 males and 30 females, divided into three groups: 20 animals treated with Deposteron® (testosterone cypionate); another 20 animals were treated with Winstrol Depot® (stanozolol); the last 20 animals were treated with saline solution. All the animals were submitted to swimming for 15 minutes. After the treatment, the animals were euthanized by halothane inhalation (Halotano) method. The brains were removed and stored in 4% formal-dehyde solution for 24 hours. From each brain, homotypic samples were taken from the middle region of the brain in frontal cuts so that we could evaluate the areas established for this study. Results: Analyzes of the estimated cell profiles showed that there was a decrease in the number of profiles in the pallidal nucleus of the male animals treated with Winstrol Depot®. Conclusion: These results allow us to infer that inadequate and non-medical use of AAS can lead to cellular degeneration.

RESUMEN Objetivos: Poco se sabe acerca del efecto de la acción de los esteroides anabólicos androgénicos (EAA) en el cerebro humano y, por este motivo, decidimos estudiar la pérdida neuronal causada por el uso y abuso de EAA en ratones. Métodos: Utilizamos 60 ratones de linaje Swiss, siendo 30 machos y 30 hembras, divididos en tres grupos: 20 animales fueron tratados con Deposteron® (cipionato de testosterona); otros 20 animales fueron tratados con Winstrol Depot® (stanozolol); los últimos 20 animales fueron tratados con solución salina. Todos fueron sometidos a natación durante 15 minutos. Terminado el tratamiento, los animales fue-ron sacrificados por el método de inhalación de Halotano. Los cerebros fueron retirados y almacenados en solución de formaldehído al 4% durante 24 horas. De cada cerebro fueron retiradas muestras homotípicas de la región media del cerebro en cortes frontales, así que pudimos evaluar las áreas establecidas para este estudio. Resultados: El análisis de la estimación de los perfiles celulares mostró que hubo una disminución en el número de perfiles en el globo pálido de los animales machos tratados con Winstrol Depot®. Conclusión: Estos resultados permiten inferir que el uso inadecuado y sin orientación médica de EAA puede conducir a la degeneración celular.

Aciduria glutárica tipo I / Glutaric aciduria, type I

La aciduria glutárica tipo I se produce por deficiencia de la enzima glutaril-CoA deshidrogenasa involucrada en el catabolismo de la L-lisina, L-hidroxilisina y L-triptófano lo que ocasiona acumulación de los ácidos glutárico y 3 hidroxiglutárico responsables del compromiso neurológico severo característico de esta enfermedad. La sospecha y diagnóstico de las enfermedades metabólicas constituyen un reto para el personal de salud dada su baja incidencia. En el caso de la aciduria glutárica tipo I se trata de una enfermedad para la cual se poseen los recursos técnicos para el diagnóstico y tratamiento nutricional, su instauración previa a la aparición de encefalopatía aguda, que ocasionan daños irreversibles en el sistema nervioso central, mejora el pronóstico y disminuye el grado de discapacidad. En esta publicación se reportan 5 casos con diagnóstico clínico y bioquímico de aciduria glutárica tipo I que ilustran el espectro clínico y el proceso diagnóstico y de tratamiento en el medio colombiano. Los pacientes se encuentran en seguimiento por los servicios de Neuropediatría.

Glutaric aciduria type i is a disorder resulting trom the deficiency ot the glutaryl-CoA dehydrogenase, enzyme involved in the catabolism ot L-lysine, L-hydroxy-lysine y L-tryptophan causing the accumulation ot its derivatives glutaric acid and 3-hydroxy-glutaric acid which are responsible tor the severe neurological involvement observed in this disease. The diagnosis ot metabolic disorders represents a challenge tor health-care services given its low incidence. Glutaric aciduria type I is a disease tor which there are available technical resources tor diagnosis as well as the nutritional therapy that when set prior to acute encephalopathy, who results in irreversible damage ot central nervous system, can improve the prognosis and decrease the disability ot patients. This publication report 5 cases with clinical and biochemical diagnosis ot glutaric aciduria type i that show the clinical spectrum the diagnostic and treatment approach ot this pathology in Colombia. All the patients are being followed by neuropediatrics services.